Valuation: Sera Prognostics, Inc.

Market Cap 70.88M 62.06M 57.29M 53.5M 101M 6.7B 103M 689M 266M 3.31B 266M 260M 11.48B P/E 2026 *
-2.76x
P/E 2027 * -3.23x
Enterprise Value 70.88M 62.06M 57.29M 53.5M 101M 6.7B 103M 689M 266M 3.31B 266M 260M 11.48B EV / Sales 2026 *
196x
EV / Sales 2027 * 26.5x
Free-Float
86.29%
Yield 2026 *
-
Yield 2027 * -
1 day+4.42%
1 week+2.72%
Current month-12.50%
1 month-13.70%
3 months-1.56%
6 months-34.83%
Current year-35.93%
1 week 1.74
Extreme 1.74
1.9
1 month 1.72
Extreme 1.725
2.33
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
15.5
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 15/05/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 68 29/11/2021
Chairman 74 20/04/2011
Chairman 59 08/06/2023
Date Insider Type Main position Quantity % Market Cap.
06-11Sell

Chief Financial Officer

-2,037 0.0053%
06-11Sell

Executive/Senior Manager

-4,739 0.0124%
06-11Sell

Chief Technology Officer

-362 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+4.42%+2.72%-31.77%-42.64% 70.88M
+0.07%+4.16%+17.04%+11.42% 23.01B
+2.12%+10.41%+37.25% - 20.17B
-4.05%+7.98%+80.39%+51.96% 3.5B
+1.92%-5.34%+20.28%-29.78% 3.4B
-3.31%+15.94%+240.74%+238.15% 2.51B
-6.18%-5.93%+235.98%+305.58% 1.96B
-0.80%-0.86%-26.63% - 1.81B
-0.17%-6.57%-34.38%-41.47% 1.72B
-0.72%-6.28%+4.49%-10.89% 1.62B
Average -0.64%+2.53%+54.34%+60.29% 5.98B
Weighted average by Cap. +0.24%+6.00%+41.13%+38.32%

Financials

2026 *2027 *
Net sales 362K 317K 293K 274K 515K 34.27M 527K 3.53M 1.36M 16.91M 1.36M 1.33M 58.7M 2.68M 2.34M 2.16M 2.02M 3.8M 253M 3.89M 26.02M 10.05M 125M 10.05M 9.83M 433M
Net income -33.26M -29.12M -26.89M -25.11M -47.26M -3.14B -48.34M -324M -125M -1.55B -125M -122M -5.39B -29.98M -26.25M -24.23M -22.63M -42.6M -2.83B -43.57M -292M -113M -1.4B -113M -110M -4.85B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
30/06/26 $1.890 +4.42% 19,570
29/06/26 $1.810 +0.56% 12,190
26/06/26 $1.800 0.00% 46,311
25/06/26 $1.800 0.00% 32,252
24/06/26 $1.800 -2.17% 29,349
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.810USD
Average target price
5.500USD
Spread / Average Target
+203.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock